The approval is backed by a biomarker subgroup analysis of the PAOLA-1 Phase III trial. Credit: Nephron

AstraZeneca and Merck’s (MSD) Lynparza (olaparib) has secured approval from the European Commission for prostate cancer and ovarian cancer treatments in the European Union (EU).

Lynparza is a first PARP inhibitor and targeted treatment to inhibit DNA damage response (DDR) in cells / tumours harbouring a deficiency in homologous recombination repair (HRR).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

EC approved Lynparza for treating patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1 / 2) mutations, a subpopulation of HRR gene mutations.

A subgroup analysis of the PROfound Phase III trial of Lynparza backs the prostate cancer approval.

According to trial data, the drug showed a substantial improvement in radiographic progression-free survival (rPFS) and overall survival (OS) versus enzalutamide or abiraterone in men with BRCA1 / 2 mutations.

AstraZeneca Oncology Business Unit executive vice-president Dave Fredrickson said: “This approval means BRCA testing should now become a critical step in the diagnosis and determination of treatment for men with advanced prostate cancer in the EU.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lynparza also received EU approval for the first-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer, backed by a biomarker subgroup analysis of the PAOLA-1 Phase III trial of Lynparza in combination with bevacizumab maintenance treatment.

Results of the trial showed a substantial PFS improvement in Lynparza plus bevacizumab arm compared with bevacizumab alone in patients with HRD-positive advanced ovarian cancer.

In September, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended for the approval in both prostate and ovarian cancer treatments.

The US Food and Drug Administration (FDA) granted priority review for Lynparza plus bevacizumab to treat advanced ovarian cancer in January.